Fetzima Patent Expiration

Fetzima is a drug owned by Abbvie Inc. It is protected by 3 US drug patents filed from 2013 to 2014 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 23, 2032. Details of Fetzima's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US8865937 Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(7 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481598 Stable dosage forms of levomilnacipran
Mar, 2031

(6 years from now)

Active
USRE43879 Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
Jan, 2026

(1 year, 2 months from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fetzima's patents.

Given below is the list of recent legal activities going on the following patents of Fetzima.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 09 Mar, 2022 US8865937
Payment of Maintenance Fee, 8th Year, Large Entity 11 Jan, 2021 US8481598
Payment of Maintenance Fee, 4th Year, Large Entity 23 Apr, 2018 US8865937
Recordation of Patent Grant Mailed 21 Oct, 2014 US8865937
Patent Issue Date Used in PTA Calculation 21 Oct, 2014 US8865937
Email Notification 03 Oct, 2014 US8865937
Issue Notification Mailed 01 Oct, 2014 US8865937
Email Notification 22 Sep, 2014 US8865937
Mail Response to 312 Amendment (PTO-271) 22 Sep, 2014 US8865937
Dispatch to FDC 19 Sep, 2014 US8865937


FDA has granted several exclusivities to Fetzima. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Fetzima, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Fetzima.

Exclusivity Information

Fetzima holds 3 exclusivities out of which 2 have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Fetzima's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
NCE*(NCE*) Jul 25, 2018
M(M-249) Oct 07, 2022
M(M-304) Mar 24, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Fetzima is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fetzima's family patents as well as insights into ongoing legal events on those patents.

Fetzima's Family Patents

Fetzima has patent protection in a total of 4 countries. It has a significant patent presence in the US with 68.4% of its patents being US patents. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Fetzima.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Fetzima's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 23, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Fetzima Generics:

Levomilnacipran Hydrochloride is the generic name for the brand Fetzima. 4 different companies have already filed for the generic of Fetzima, with Amneal Pharms Co having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Fetzima's generic

How can I launch a generic of Fetzima before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Fetzima's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Fetzima's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Fetzima -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
20 mg, 40 mg, 80 mg and 120 mg 25 Jul, 2017 6 04 Feb, 2019 02 Mar, 2031 Eligible

Alternative Brands for Fetzima

Fetzima which is used for treating Major Depressive Disorder (MDD)., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Abbvie
Viibryd Used for treating major depressive disorder (MDD).
Astrazeneca
Seroquel Xr Used for treating major depressive disorder (MDD) and schizophrenia.
Osmotica Pharm Us
Venlafaxine Hydrochloride Used for treating major depressive disorder (MDD) and social anxiety disorder.
Otsuka
Abilify Used for treating manic episodes in bipolar disorder, major depressive disorder, irritability in autistic disorder, and maintaining stability in schizophrenia.





About Fetzima

Fetzima is a drug owned by Abbvie Inc. It is used for treating Major Depressive Disorder (MDD). Fetzima uses Levomilnacipran Hydrochloride as an active ingredient. Fetzima was launched by Abbvie in 2013.

Approval Date:

Fetzima was approved by FDA for market use on 25 July, 2013.

Active Ingredient:

Fetzima uses Levomilnacipran Hydrochloride as the active ingredient. Check out other Drugs and Companies using Levomilnacipran Hydrochloride ingredient

Treatment:

Fetzima is used for treating Major Depressive Disorder (MDD).

Dosage:

Fetzima is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 40MG BASE CAPSULE, EXTENDED RELEASE Prescription ORAL
EQ 120MG BASE CAPSULE, EXTENDED RELEASE Prescription ORAL
EQ 80MG BASE CAPSULE, EXTENDED RELEASE Prescription ORAL
EQ 20MG BASE CAPSULE, EXTENDED RELEASE Prescription ORAL